Joanne Yang
Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.
We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.
Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.
We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.
Syneos Health
Director, Business DevelopmentSimon Yi
PhysioCue is digital health and therapy device development company, located in the heart of Silicon Valley, California. PhysioCue has developed the thermal neurostimulation technology for a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.
Wayne Yin
We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”
Simcere Pharmaceutical Group
BD DirectorXudong Yuan
Acon Pharmaceuticals Inc. (Acon Pharma) is a specialty pharmaceutical company and focuses on BLA, ANDA, and 505(b)(2) NDA drug product development with its captive drug delivery system technology platforms. Acon Pharma provides service to its partners and customers to accelerate their IND and NDA product development by out-licencing its captive drug delivery platforms, pre-formulation, formulation, process development, and manufacturing of different types of dosage forms and drug delivery products. Our expertise covers drug development and delivery of poorly soluble small molecule drugs, siRNA, oligonucleotides, peptides, protein, and plasmid DNA. Our formulation technology platforms include nanoparticles, microspheres / microparticles, nanocrystals, liposome, implant, long-acting injectable, oral fast dissolving film (ODF), transdermal patches, resinate / polistirex suspension, nasal spray, topical cream, gel, ointment, nanoemulsion, microemulsion, self-emulsifying system, tablets, capsules, inhalers, controlled release, modified release, and delayed release.
Acon Pharma
CEOKun Yuan
GEMSEKI facilitates partnering and licensing activities by using web platform and actively reaching out to potential licensees effectively.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.
GEMSEKI launched in Oct 2017 as a subsidiary of SNBL a public Japanese company (Tokyo Stock Exchange 2395:JP)
We are looking for assets for in-licensing opportunities of our clients.
Also we have several Japanese and non-Japanese assets in oncology, infection, RA/OA , pain and rheumatoid arthritis available for out-licensing.